$MPLT

Catalyst4, Inc. purchased $50.1M of MPLT (indirect holdings)

Catalyst4, Inc. purchased 4,400,000 indirectly-held shares of MapLight Therapeutics, Inc. (MPLT) at $11.38 ($50.07M total) on 2026-08-14.

Original reporting
SEC EDGAR · Catalyst4, Inc.
Published Aug 18, 2026, 10:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
9/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

Traders may monitor for follow-through buying or selling by related holders, but the filing alone does not provide new clinical, regulatory, or financial guidance.

02

Market read

A large 10% owner added roughly $50.1M of MPLT shares, which can modestly support sentiment but lacks fundamental catalysts in the text.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not disclose the investment thesis, timing constraints, or whether other holders are also changing positions.

Relevance 9/10Novelty 5/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction disclosure: Catalyst4, Inc. (10% owner) bought MPLT shares indirectly via an open-market purchase.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

Catalyst4, Inc. filed a Form 4 showing an indirect open-market purchase of 4.4M MPLT shares for about $50.1M.

Expected impact

Near-term impact is likely limited; any reaction would be sentiment-driven rather than driven by new operating information.

Evidence & confidence

Form 4 insider transactions can influence sentiment, but the article provides no new MPLT-specific business catalyst beyond the purchase details.

Market effects

Minimal, as this is a single-company ownership transaction with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

The purchase may reflect routine portfolio rebalancing or indirect holdings mechanics, so it may not indicate a change in MPLT fundamentals.

Key entities

  • MapLight Therapeutics, Inc.

    Subject of the Form 4 insider transaction, ticker MPLT.

  • Catalyst4, Inc.

    Reporter of the Form 4, disclosed an indirect open-market purchase of MPLT shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Results of Operations and Financial Condition

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 3 d48818dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of August 13, 2026, by and among MapLight Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each of the purcha

$MPLTMedAI 8/10

MapLight Therapeutics, Inc.: MapLight Therapeutics Announces $150 Million Private Placement Financing

MapLight Therapeutics (Nasdaq: MPLT) announced a $150 million PIPE private placement. It will sell 9,197,887 common shares at $11.38 and pre-funded warrants for up to 3,983,168 shares at $11.3799, with an exercise price of $0.0001. Proceeds will fund ML-007C-MA (VISTA Phase 2 and ZEPHYR-2 Phase 3) and working capital. Expected close Aug. 14, 2026.